Jan 16, 2024
Alex Nemiroff, General Counsel at Praxis Precision Medicines, focuses on developing life-altering treatments for pediatric patients with epilepsy, particularly those with genetic epilepsies known as Developmental Epileptic Encephalopathies- DEEs. Praxis targets specific gene mutations SCN2A and SCN8A with therapies...
Jan 16, 2024
Alex Nemiroff, General Counsel at Praxis Precision Medicines, focuses on developing life-altering treatments for pediatric patients with epilepsy, particularly those with genetic epilepsies known as Developmental Epileptic Encephalopathies- DEEs. Praxis targets specific gene mutations SCN2A and SCN8A with therapies...
Oct 3, 2023
Dr. Eliseo Salinas, head of Research and Development at Delix Therapeutics, is focused on developing drugs to treat central nervous system disorders by addressing synaptic density. Applying knowledge about psychoplastogens and neuroplastogens, Delix strives to increase connections between neurons in...
Oct 3, 2023
Dr. Eliseo Salinas, head of Research and Development at Delix Therapeutics, is focused on developing drugs to treat central nervous system disorders by addressing synaptic density. Applying knowledge about psychoplastogens and neuroplastogens, Delix strives to increase connections between neurons in...
May 18, 2023
Dr. Spyros Papapetropoulos is the President and CEO of Bionomics, a biotech company focused on central nervous system disorders, particularly social anxiety, and post-traumatic stress disorders. Social anxiety is a disease primarily of adolescents and young adults, and the social isolation during COVID contributed to...